抗髓鞘相关糖蛋白神经病：最新进展
Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.
作者信息
Morganroth Jennifer, Karam Chafic
机构信息
Department of Neurology, University of Pennsylvania.
出版信息
Neurol Clin Pract. 2025 Feb;15(1):e200368. doi: 10.1212/CPJ.0000000000200368. Epub 2024 Oct 8.
Abstract
BACKGROUND
The purpose of this review is to give an update on myelin-associated glycoprotein (MAG) neuropathy.
RECENT FINDINGS
There are several recent developments in anti-MAG neuropathy, with the major one being the retrospective analysis of 50 clinical trials that showed that at least a 50% reduction in anti-MAG levels is associated with a therapeutic response. Other updates address antibody levels needed for a positive test, response, and exacerbations to therapy and the type of antibody more associated with malignancy.
IMPLICATIONS FOR PRACTICE
Anti-MAG neuropathy is heterogeneous, and the natural history of the disease continues to be refined. Treatment options are being explored for refractory disease.
摘要
背景
本综述的目的是更新关于髓鞘相关糖蛋白（MAG）神经病的信息。
最新发现
抗MAG神经病有几项最新进展，其中主要的一项是对50项临床试验的回顾性分析，该分析表明抗MAG水平至少降低50%与治疗反应相关。其他更新内容涉及阳性检测、反应和治疗加重所需的抗体水平，以及与恶性肿瘤更相关的抗体类型。
对实践的启示
抗MAG神经病具有异质性，该疾病的自然史仍在不断完善。正在探索针对难治性疾病的治疗选择。
相似文献
1
Anti-Myelin-Associated Glycoprotein Neuropathy: Recent Developments.抗髓鞘相关糖蛋白神经病：最新进展
Neurol Clin Pract. 2025 Feb;15(1):e200368. doi: 10.1212/CPJ.0000000000200368. Epub 2024 Oct 8.
2
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.IgM抗髓鞘相关糖蛋白副蛋白相关周围神经病的免疫治疗
Cochrane Database Syst Rev. 2016 Oct 4;10(10):CD002827. doi: 10.1002/14651858.CD002827.pub4.
3
Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.IgM抗髓鞘相关糖蛋白副蛋白相关周围神经病的免疫治疗
Cochrane Database Syst Rev. 2012 May 16(5):CD002827. doi: 10.1002/14651858.CD002827.pub3.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
7
Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review.左乙拉西坦添加治疗耐药性局灶性癫痫：Cochrane系统评价的更新版
Cochrane Database Syst Rev. 2012 Sep 12;2012(9):CD001901. doi: 10.1002/14651858.CD001901.pub2.
8
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over.不同吸入性糖皮质激素及其与长效β2受体激动剂联合使用治疗12岁及以上成人和儿童慢性哮喘比较效果的系统评价与经济学分析
Health Technol Assess. 2008 May;12(19):iii-iv, 1-360. doi: 10.3310/hta12190.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
10
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织（EORTC）癌症贫血患者促红细胞生成蛋白使用指南：2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
本文引用的文献
1
Anti-myelin-associated glycoprotein neuropathy: Where do we stand?抗髓鞘相关糖蛋白神经病：我们处于什么位置？
Muscle Nerve. 2023 Nov;68(6):823-832. doi: 10.1002/mus.27954. Epub 2023 Aug 21.
2
Decrease in Serum Anti-MAG Autoantibodies Is Associated With Therapy Response in Patients With Anti-MAG Neuropathy: Retrospective Study.血清抗 MAG 自身抗体减少与抗 MAG 神经病患者的治疗反应相关：回顾性研究。
Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1). doi: 10.1212/NXI.0000000000001109. Print 2022 Jan.
3
Anti-MAG neuropathy: From biology to clinical management.抗髓鞘相关糖蛋白抗体神经病：从生物学到临床管理。
J Neuroimmunol. 2021 Dec 15;361:577725. doi: 10.1016/j.jneuroim.2021.577725. Epub 2021 Sep 28.
4
Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy.商业 ELISA 检测抗 MAG 抗体在神经病变患者中的敏感性和特异性。
J Neuroimmunol. 2020 Aug 15;345:577288. doi: 10.1016/j.jneuroim.2020.577288. Epub 2020 Jun 8.
5
The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy.布鲁顿酪氨酸激酶抑制剂伊布替尼可改善抗髓鞘少突胶质细胞糖蛋白抗体相关性多发性神经病。
Neurol Neuroimmunol Neuroinflamm. 2020 Apr 13;7(4). doi: 10.1212/NXI.0000000000000720. Print 2020 Jul.
6
Selective inhibition of anti-MAG IgM autoantibody binding to myelin by an antigen-specific glycopolymer.一种抗原特异性糖聚物选择性抑制抗 MAG IgM 自身抗体与髓鞘的结合。
J Neurochem. 2020 Sep;154(5):486-501. doi: 10.1111/jnc.15021. Epub 2020 Jun 23.
7
Rituximab-associated neuropathy: About two cases.利妥昔单抗相关的神经病变：约两例。
Eur J Intern Med. 2020 Jun;76:102-103. doi: 10.1016/j.ejim.2020.03.011. Epub 2020 Mar 16.
8
Relevance of anti-HNK1 antibodies in the management of anti-MAG neuropathies.抗 HNK1 抗体在抗 MAG 神经病治疗中的相关性。
J Neurol. 2019 Aug;266(8):1973-1979. doi: 10.1007/s00415-019-09367-0. Epub 2019 May 14.
9
Clinical and laboratory features of anti-MAG neuropathy without monoclonal gammopathy.抗髓鞘相关糖蛋白抗体神经病的临床和实验室特征，不伴单克隆丙种球蛋白血症。
Sci Rep. 2019 Apr 16;9(1):6155. doi: 10.1038/s41598-019-42545-8.
10
Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy.奥妥珠单抗，一种强效抗B细胞药物，用于治疗对利妥昔单抗无反应的IgM抗MAG神经病变。
Neurol Neuroimmunol Neuroinflamm. 2018 Apr 5;5(4):e460. doi: 10.1212/NXI.0000000000000460. eCollection 2018 Jul.
Zotero 插件